Cargando…
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a cas...
Autores principales: | Viscuse, Paul V., Marques-Piubelli, Mario L., Heberton, Meghan M., Parra, Edwin Roger, Shah, Amishi Y., Siefker-Radtke, Arlene, Gao, Jianjun, Goswami, Sangeeta, Ivan, Doina, Curry, Jonathan L., Campbell, Matthew T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970171/ https://www.ncbi.nlm.nih.gov/pubmed/33747934 http://dx.doi.org/10.3389/fonc.2021.621591 |
Ejemplares similares
-
Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction
por: Bansal, Aditi, et al.
Publicado: (2022) -
A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
por: Francis, Andrea, et al.
Publicado: (2020) -
Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions
por: Zimmerman, Danielle, et al.
Publicado: (2019) -
Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
por: Mimura, Yuji, et al.
Publicado: (2022) -
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
por: Dobry, Allison S., et al.
Publicado: (2021)